Home » Authors » Brady Huggett

Articles by Brady Huggett

Geron, Riding Positive News, Getting Up To $24M In Funding

April 9, 2003

By Brady Huggett

A wave of positive news, its lead product approaching the clinic and, now, two years of cash in the bank led Geron Corp. President and CEO Thomas Okarma to label the current period in Geron's history its "coming-out party." (BioWorld Today)

Geron, Riding Positive News, Getting Up To $24M In Funding

April 9, 2003

By Brady Huggett

A wave of positive news, its lead product approaching the clinic and, now, two years of cash in the bank led Geron Corp. President and CEO Thomas Okarma to label the current period in Geron's history its "coming-out party." (BioWorld Today)

With MemRx Acquisition, Sagres Gains Intracellular Capabilities

April 4, 2003

By Brady Huggett

With MemRx Acquisition, Sagres Gains Intracellular Capabilities

April 4, 2003

By Brady Huggett

Isis Cuts Staff, Curbs Programs Following Failure Of Affinitak

April 3, 2003

By Brady Huggett

Isis Cuts Staff, Curbs Programs Following Failure Of Affinitak

April 3, 2003

By Brady Huggett

SIGA Eyes Plexus To Expand Biowarfare Defense Research

April 2, 2003

By Brady Huggett

Array Lowers Forecast Due To 'Soft' Collaborative Environment

April 2, 2003

By Brady Huggett

SIGA Eyes Plexus To Expand Biowarfare Defense Research

April 2, 2003

By Brady Huggett

Array Lowers Forecast Due To 'Soft' Collaborative Environment

April 2, 2003

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...